These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27725433)

  • 1. Investigation of Appropriate Inhalation Technique for Mometasone Furoate Dry Powder Inhaler.
    Yokoyama H; Ito K; Mihashi H; Shiraishi Y; Takayanagi R; Yamada Y
    Biol Pharm Bull; 2016; 39(10):1576-1580. PubMed ID: 27725433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug delivery performance of the mometasone furoate dry powder inhaler.
    Yang TT; Li S; Wyka B; Kenyon D
    J Aerosol Med; 2001; 14(4):487-94. PubMed ID: 11791689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Particle size and small airway effects of mometasone furoate delivered by dry powder inhaler.
    Berger R; Berger WE
    Allergy Asthma Proc; 2013; 34(1):52-8. PubMed ID: 23406936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder.
    Yang MY; Verschuer J; Shi Y; Song Y; Katsifis A; Eberl S; Wong K; Brannan JD; Cai W; Finlay WH; Chan HK
    Int J Pharm; 2016 Nov; 513(1-2):294-301. PubMed ID: 27639621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma.
    Hua JL; Ye XF; Du CL; Xie N; Zhang JQ; Li M; Zhang J
    BMC Pulm Med; 2021 Sep; 21(1):302. PubMed ID: 34560863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers.
    Ghosh S; Ohar JA; Drummond MB
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):381-387. PubMed ID: 28933581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deposition and fine particle production during dynamic flow in a dry powder inhaler: a CFD approach.
    Milenkovic J; Alexopoulos AH; Kiparissides C
    Int J Pharm; 2014 Jan; 461(1-2):129-36. PubMed ID: 24296048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery.
    Liu S; Watts AB; Du J; Bui A; Hengsawas S; Peters JI; Williams RO
    Eur J Pharm Biopharm; 2015 Oct; 96():132-42. PubMed ID: 26220015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring Inhaler Inhalations Using an Acoustic Sensor Proximal to Inhaler Devices.
    Taylor TE; Holmes MS; Sulaiman I; Costello RW; Reilly RB
    J Aerosol Med Pulm Drug Deliv; 2016 Oct; 29(5):439-446. PubMed ID: 26859629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients.
    Harb HS; Laz NI; Rabea H; Abdelrahim MEA
    Eur J Pharm Sci; 2020 Apr; 147():105298. PubMed ID: 32151707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD.
    Ghosh S; Pleasants RA; Ohar JA; Donohue JF; Drummond MB
    Int J Chron Obstruct Pulmon Dis; 2019; 14():585-595. PubMed ID: 30880948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers.
    Bhagwat S; Schilling U; Chen MJ; Wei X; Delvadia R; Absar M; Saluja B; Hochhaus G
    Pharm Res; 2017 Dec; 34(12):2541-2556. PubMed ID: 28799097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.
    Delvadia RR; Wei X; Longest PW; Venitz J; Byron PR
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):196-206. PubMed ID: 26447531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma.
    Zeidler M; Corren J; Tashkin DP
    Curr Med Res Opin; 2010 Jun; 26(6):1295-305. PubMed ID: 20370376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can patients achieve sufficient peak inspiratory flow rate (PIFR) with Turbuhaler® during acute exacerbation of asthma?
    Mohd Rhazi NA; Muneswarao J; Abdul Aziz F; Ibrahim B; Kamalludin A; Soelar SA
    J Asthma; 2023 Aug; 60(8):1608-1612. PubMed ID: 36650693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
    Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exhalation immediately before inhalation optimizes dry powder inhaler use.
    Kondo T; Hibino M; Tanigaki T; Ohe M; Kato S
    J Asthma; 2015; 52(9):935-9. PubMed ID: 26513654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates.
    DeLong M; Wright J; Dawson M; Meyer T; Sommerer K; Dunbar C
    J Aerosol Med; 2005; 18(4):452-9. PubMed ID: 16379620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
    O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN
    Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.